Related Experiment Video

Updated: Oct 22, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.1K

Adverse Drug Reactions Following Propranolol in Infantile Hemangioma

Vaibhav Pandey1, Preeti Tiwari2, Mohammed Imran1

  • 1Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh.

Indian Pediatrics
|September 1, 2021
PubMed

Insights

Propranolol is effective for infantile hemangioma, but young children with low body weight face higher risks of adverse effects like diarrhea and sleep disturbances.

Area of Science:

  • Pediatric dermatology
  • Pharmacology

Background:

  • Infantile hemangioma (IH) is a common vascular tumor in infants.
  • Propranolol is a first-line treatment for IH, but its safety profile requires evaluation.

Purpose of the Study:

  • To assess the adverse effects of propranolol therapy in infantile hemangioma.
  • Identify risk factors associated with propranolol-induced adverse events.

Main Methods:

  • An ambispective study was conducted from August 2011 to December 2019.
  • Retrospective review of case records and prospective identification of adverse reactions based on predefined criteria.

Main Results:

  • Out of 514 patients, 82 (15.9%) experienced adverse effects.
  • Diarrhea with weight loss (32.9%) and irritability with decreased sleep (25.6%) were most common.
  • Younger age, low body weight, and early onset were risk factors for severe adverse reactions.

Conclusions:

  • Young children with low body weight are at increased risk for propranolol adverse effects.
  • Careful monitoring is essential, especially in high-risk infants receiving propranolol for IH.
Abstract

More Related Videos

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

6.8K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.1K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
808
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.0K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
287